The UK and US have forged a major commercial pact that will maintain no tariffs on British drug products going into the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has committed to raise funding on medicines through the National Health Service (NHS). This move ensures that tariffs on these vital goods will stay at nothing for a duration of three years.
This deal comes after recent threats to significantly raise import taxes on branded drug imports, with potential rates mentioned reaching double the cost.
"This arrangement with the Britain bolsters the global environment for cutting-edge drugs and introduces long-overdue equity to U.S.–U.K. pharmaceutical trade," a statement declared.
Commercial Importance
Drugs are one of the the United Kingdom's most significant exports to the US, which is clearly the largest market for leading UK drugmakers.
Trade data show that in the one-year period to the end of the third quarter, the UK shipped pharmaceutical products worth £11.1bn to the US. This amount made up nearly one-fifth of British export trade in that span.
"This guarantee secures employment, stimulates capital expenditure and sets the stage for the UK to become a global hub for life sciences," a government official remarked.
Specific NHS Changes
The agreement entails several key changes from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it judges new treatments to be too expensive by 25%.
- Higher Drug Budget: There is a target to raise overall NHS spending on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Payback Limit: The percentage manufacturers must refund to the NHS to control costs will be limited at 15%. Last year, repayments were more than twenty percent.
Industry Background
The deal follows a protracted row between the pharmaceutical industry and the UK government over medicine costs and NHS adoption.
These tensions were heightened by claims that US consumers were charged a premium for the equivalent treatments than patients in the Britain and the EU.
Recently, several large manufacturing plans in the UK have been delayed or cancelled, while substantial funding commitments have been pledged toward projects in the United States.
One official acknowledged that the NHS must increase expenditure on medicines, noting that its spending on drugs had shrunk as a proportion of its total funding over the previous ten-year period.
